Add Yahoo as a preferred source to see more of our stories on Google. In people with type 1 diabetes, insulin must be taken every day as their pancreas cannot produce the hormone itself. However a new ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...

One trial found that using injectable insulin icodec once a week was as effective as using a standard injectable form of insulin once a day. The other trial found that it seems to be safe and ...

The approval of Eli Lilly’s Mounjaro (tirzepatide) KwikPen by India’s Central Drugs Standard Control Organisation (CDSCO) marks a significant development in diabetes and obesity management, not only ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Insulin efsitora was noninferior to once-daily insulins ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...

India faces one of the world's largest burdens of type-2 diabetes, with an estimated 101 million adults affected, second only to China. At the same time, obesity and its metabolic consequences are ...